RxDoctor Payments DataLook up a doctor →

Patricia Lo Russo, DO

Medical Oncology · Detroit, MINPI 1932146420

Payments from drug & device makers

$24,641,569in general payments, 2019–2025

Across 3,654 payments — averaging $6743.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$3.4M
  • Genentech, Inc.$2.8M
  • AstraZeneca$2.2M
  • Pfizer$2.1M
  • Boehringer Ingelheim$1.7M
  • Astellas Pharma Inc$1.6M
  • plus $10.7M from 48 others
$41,218in research payments, 2019–2025

Across 35 payments — averaging $1177.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$12K
  • Pfizer$11K
  • Halozyme Inc$6K
  • Eli Lilly$5K
  • Amgen$4K
  • AbbVie$2K
  • plus $744 from 1 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited21$3,397,647
Genentech, Inc.432$2,824,172
AstraZeneca25$2,217,721
Pfizer(2 entities)211$2,142,072
Boehringer Ingelheim95$1,702,044
Astellas Pharma Inc465$1,628,940
Takeda Pharmaceuticals U.S.A., Inc.164$1,589,190
Merck246$1,537,888
AbbVie268$1,328,083
Boehringer Ingelheim Pharma GmbH & Co.kg99$759,593
E.r. Squibb & Sons, L.L.C.10$611,882
GSK180$581,001
Novartis13$437,061
Bayer62$419,239
Otsuka Pharmaceutical Co., Ltd.64$392,757
Eli Lilly14$357,285
Biontech SE79$350,371
Stemline Therapeutics Inc.44$273,316
EMD Serono, Inc.335$253,912
Sanofi US Services Inc.28$207,148
Mirati Therapeutics, Inc.14$186,116
Tesaro, Inc.30$183,233
Radius Health, Inc.28$164,271
Roche Products Limited193$159,814
Day One Biopharmaceuticals35$146,912
Boehringer Ingelheim International GmbH133$108,366
Seagen Inc.9$86,318
Modernatx, Inc.27$67,132
Genmab A/s9$64,979
Incyte Corporation174$63,771
Taiho Oncology, Inc.16$61,302
Hoffmann-la Roche Limited9$54,889
Exelixis Inc.23$52,051
Amgen22$45,812
Genmab U.S., Inc.10$26,366
Daiichi Sankyo Inc.3$21,414
F. Hoffmann-la Roche AG9$19,518
Merck Healthcare Kgaa5$17,221
Beigene, Ltd.1$16,965
ADC Therapeutics America, Inc.10$16,679
Array Biopharma Inc1$11,449
EMD Serono Research & Development Institute, Inc.2$11,121
Genentech USA, Inc.16$10,278
Ipsen Biopharmaceuticals, Inc4$9,240
Kyowa Kirin, Inc.4$5,642
SK Life Science, Inc.2$5,338
Foundation Medicine, Inc.1$4,758
Astellas Pharma Global Development1$3,458
Beigene AUS Pty Ltd2$2,050
Bristol Myers Squibb1$1,321
Janssen Research & Development, LLC1$1,320
Jazz Pharmaceuticals Inc.1$1,000
Gilead1$97
Lilly USA, LLC2$48

How this compares

$24,641,569 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in Michigan.

See all medical oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$10,812
Medicare patients
26
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →